ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global PD-1 and PD-L1 Immunotherapy Market Insights, Forecast to 2030
Published Date: December 2024
|
Report Code: QYRE-Auto-29O13220
Home | Market Reports | Health| Health Conditions| Cancer
Global PD 1 PD L1 Immunotherapy Market Research Report 2023
BUY CHAPTERS

Global PD-1 and PD-L1 Immunotherapy Market Insights, Forecast to 2030

Code: QYRE-Auto-29O13220
Report
December 2024
Pages:114
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Astrazeneca plc
GlaxoSmithKline PLC
Novartis
Pfizer Inc
Bristol–Myers Squibb
F.Hoffmann-La Roche
Merck
Roche
Jiangsu Hengrui Medicine
Innovent
Eli Lilly

PD-1 and PD-L1 Immunotherapy Market

Market Analysis and Insights: Global PD-1 and PD-L1 Immunotherapy Market
The global PD-1 and PD-L1 Immunotherapy market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for PD-1 and PD-L1 Immunotherapy is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for PD-1 and PD-L1 Immunotherapy is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The Europe market for PD-1 and PD-L1 Immunotherapy is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The global key companies of PD-1 and PD-L1 Immunotherapy include AstraZeneca, Bristol-Myers Squibb, F. Hoffmann-La Roche, Merck, Pfizer, Roche, Novartis, Jiangsu HengRui Medicine and Innovent, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
PD-1 and PD-L1 Immunotherapy is widely used in various fields, such as Solid Tumors and Blood-related Tumors, etc. Solid Tumors provides greatest supports to the PD-1 and PD-L1 Immunotherapy industry development. In 2023, global % revenue of PD-1 and PD-L1 Immunotherapy went into Solid Tumors filed and the proportion will reach to % in 2030.
Report Covers:
This report presents an overview of global market for PD-1 and PD-L1 Immunotherapy market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of PD-1 and PD-L1 Immunotherapy, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for PD-1 and PD-L1 Immunotherapy, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the PD-1 and PD-L1 Immunotherapy revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global PD-1 and PD-L1 Immunotherapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for PD-1 and PD-L1 Immunotherapy revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation

Scope of PD-1 and PD-L1 Immunotherapy Market Report

Report Metric Details
Report Name PD-1 and PD-L1 Immunotherapy Market
Segment by Type
  • PD-1 inhibitor
  • PD-L1 inhibitor
Segment by Application
  • Solid Tumors
  • Blood-related Tumors
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company AstraZeneca, Bristol-Myers Squibb, F. Hoffmann-La Roche, Merck, Pfizer, Roche, Novartis, Jiangsu HengRui Medicine, Innovent, Eli Lilly, GlaxoSmithKline
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Revenue of PD-1 and PD-L1 Immunotherapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of PD-1 and PD-L1 Immunotherapy companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
  • Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
  • Chapter 8: China by Type, and by Application, revenue for each segment.
  • Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
  • Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
  • Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PD-1 and PD-L1 Immunotherapy revenue, gross margin, and recent development, etc.
  • Chapter 12: Analyst's Viewpoints/Conclusions

FAQ for this report

Who are the main players in the PD-1 and PD-L1 Immunotherapy Market report?

Ans: The main players in the PD-1 and PD-L1 Immunotherapy Market are AstraZeneca, Bristol-Myers Squibb, F. Hoffmann-La Roche, Merck, Pfizer, Roche, Novartis, Jiangsu HengRui Medicine, Innovent, Eli Lilly, GlaxoSmithKline

What are the Application segmentation covered in the PD-1 and PD-L1 Immunotherapy Market report?

Ans: The Applications covered in the PD-1 and PD-L1 Immunotherapy Market report are Solid Tumors, Blood-related Tumors

What are the Type segmentation covered in the PD-1 and PD-L1 Immunotherapy Market report?

Ans: The Types covered in the PD-1 and PD-L1 Immunotherapy Market report are PD-1 inhibitor, PD-L1 inhibitor

Recommended Reports

Cancer Therapy Markets

Immunotherapy & Checkpoints

Cancer Diagnostics & Treatments

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global PD-1 and PD-L1 Immunotherapy Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 PD-1 inhibitor
1.2.3 PD-L1 inhibitor
1.3 Market by Application
1.3.1 Global PD-1 and PD-L1 Immunotherapy Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Solid Tumors
1.3.3 Blood-related Tumors
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global PD-1 and PD-L1 Immunotherapy Market Perspective (2019-2030)
2.2 Global PD-1 and PD-L1 Immunotherapy Growth Trends by Region
2.2.1 PD-1 and PD-L1 Immunotherapy Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 PD-1 and PD-L1 Immunotherapy Historic Market Size by Region (2019-2024)
2.2.3 PD-1 and PD-L1 Immunotherapy Forecasted Market Size by Region (2025-2030)
2.3 PD-1 and PD-L1 Immunotherapy Market Dynamics
2.3.1 PD-1 and PD-L1 Immunotherapy Industry Trends
2.3.2 PD-1 and PD-L1 Immunotherapy Market Drivers
2.3.3 PD-1 and PD-L1 Immunotherapy Market Challenges
2.3.4 PD-1 and PD-L1 Immunotherapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue PD-1 and PD-L1 Immunotherapy by Players
3.1.1 Global PD-1 and PD-L1 Immunotherapy Revenue by Players (2019-2024)
3.1.2 Global PD-1 and PD-L1 Immunotherapy Revenue Market Share by Players (2019-2024)
3.2 Global PD-1 and PD-L1 Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of PD-1 and PD-L1 Immunotherapy, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global PD-1 and PD-L1 Immunotherapy Market Concentration Ratio
3.4.1 Global PD-1 and PD-L1 Immunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by PD-1 and PD-L1 Immunotherapy Revenue in 2023
3.5 Global Key Players of PD-1 and PD-L1 Immunotherapy Head office and Area Served
3.6 Global Key Players of PD-1 and PD-L1 Immunotherapy, Product and Application
3.7 Global Key Players of PD-1 and PD-L1 Immunotherapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 PD-1 and PD-L1 Immunotherapy Breakdown Data by Type
4.1 Global PD-1 and PD-L1 Immunotherapy Historic Market Size by Type (2019-2024)
4.2 Global PD-1 and PD-L1 Immunotherapy Forecasted Market Size by Type (2025-2030)
5 PD-1 and PD-L1 Immunotherapy Breakdown Data by Application
5.1 Global PD-1 and PD-L1 Immunotherapy Historic Market Size by Application (2019-2024)
5.2 Global PD-1 and PD-L1 Immunotherapy Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America PD-1 and PD-L1 Immunotherapy Market Size (2019-2030)
6.2 North America PD-1 and PD-L1 Immunotherapy Market Size by Type
6.2.1 North America PD-1 and PD-L1 Immunotherapy Market Size by Type (2019-2024)
6.2.2 North America PD-1 and PD-L1 Immunotherapy Market Size by Type (2025-2030)
6.2.3 North America PD-1 and PD-L1 Immunotherapy Market Share by Type (2019-2030)
6.3 North America PD-1 and PD-L1 Immunotherapy Market Size by Application
6.3.1 North America PD-1 and PD-L1 Immunotherapy Market Size by Application (2019-2024)
6.3.2 North America PD-1 and PD-L1 Immunotherapy Market Size by Application (2025-2030)
6.3.3 North America PD-1 and PD-L1 Immunotherapy Market Share by Application (2019-2030)
6.4 North America PD-1 and PD-L1 Immunotherapy Market Size by Country
6.4.1 North America PD-1 and PD-L1 Immunotherapy Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America PD-1 and PD-L1 Immunotherapy Market Size by Country (2019-2024)
6.4.3 North America PD-1 and PD-L1 Immunotherapy Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe PD-1 and PD-L1 Immunotherapy Market Size (2019-2030)
7.2 Europe PD-1 and PD-L1 Immunotherapy Market Size by Type
7.2.1 Europe PD-1 and PD-L1 Immunotherapy Market Size by Type (2019-2024)
7.2.2 Europe PD-1 and PD-L1 Immunotherapy Market Size by Type (2025-2030)
7.2.3 Europe PD-1 and PD-L1 Immunotherapy Market Share by Type (2019-2030)
7.3 Europe PD-1 and PD-L1 Immunotherapy Market Size by Application
7.3.1 Europe PD-1 and PD-L1 Immunotherapy Market Size by Application (2019-2024)
7.3.2 Europe PD-1 and PD-L1 Immunotherapy Market Size by Application (2025-2030)
7.3.3 Europe PD-1 and PD-L1 Immunotherapy Market Share by Application (2019-2030)
7.4 Europe PD-1 and PD-L1 Immunotherapy Market Size by Country
7.4.1 Europe PD-1 and PD-L1 Immunotherapy Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe PD-1 and PD-L1 Immunotherapy Market Size by Country (2019-2024)
7.4.3 Europe PD-1 and PD-L1 Immunotherapy Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China PD-1 and PD-L1 Immunotherapy Market Size (2019-2030)
8.2 China PD-1 and PD-L1 Immunotherapy Market Size by Type
8.2.1 China PD-1 and PD-L1 Immunotherapy Market Size by Type (2019-2024)
8.2.2 China PD-1 and PD-L1 Immunotherapy Market Size by Type (2025-2030)
8.2.3 China PD-1 and PD-L1 Immunotherapy Market Share by Type (2019-2030)
8.3 China PD-1 and PD-L1 Immunotherapy Market Size by Application
8.3.1 China PD-1 and PD-L1 Immunotherapy Market Size by Application (2019-2024)
8.3.2 China PD-1 and PD-L1 Immunotherapy Market Size by Application (2025-2030)
8.3.3 China PD-1 and PD-L1 Immunotherapy Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia PD-1 and PD-L1 Immunotherapy Market Size (2019-2030)
9.2 Asia PD-1 and PD-L1 Immunotherapy Market Size by Type
9.2.1 Asia PD-1 and PD-L1 Immunotherapy Market Size by Type (2019-2024)
9.2.2 Asia PD-1 and PD-L1 Immunotherapy Market Size by Type (2025-2030)
9.2.3 Asia PD-1 and PD-L1 Immunotherapy Market Share by Type (2019-2030)
9.3 Asia PD-1 and PD-L1 Immunotherapy Market Size by Application
9.3.1 Asia PD-1 and PD-L1 Immunotherapy Market Size by Application (2019-2024)
9.3.2 Asia PD-1 and PD-L1 Immunotherapy Market Size by Application (2025-2030)
9.3.3 Asia PD-1 and PD-L1 Immunotherapy Market Share by Application (2019-2030)
9.4 Asia PD-1 and PD-L1 Immunotherapy Market Size by Region
9.4.1 Asia PD-1 and PD-L1 Immunotherapy Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia PD-1 and PD-L1 Immunotherapy Market Size by Region (2019-2024)
9.4.3 Asia PD-1 and PD-L1 Immunotherapy Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America PD-1 and PD-L1 Immunotherapy Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America PD-1 and PD-L1 Immunotherapy Market Size by Type
10.2.1 Middle East, Africa, and Latin America PD-1 and PD-L1 Immunotherapy Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America PD-1 and PD-L1 Immunotherapy Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America PD-1 and PD-L1 Immunotherapy Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America PD-1 and PD-L1 Immunotherapy Market Size by Application
10.3.1 Middle East, Africa, and Latin America PD-1 and PD-L1 Immunotherapy Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America PD-1 and PD-L1 Immunotherapy Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America PD-1 and PD-L1 Immunotherapy Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America PD-1 and PD-L1 Immunotherapy Market Size by Country
10.4.1 Middle East, Africa, and Latin America PD-1 and PD-L1 Immunotherapy Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America PD-1 and PD-L1 Immunotherapy Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America PD-1 and PD-L1 Immunotherapy Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca PD-1 and PD-L1 Immunotherapy Introduction
11.1.4 AstraZeneca Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
11.1.5 AstraZeneca Recent Developments
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Details
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Introduction
11.2.4 Bristol-Myers Squibb Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
11.2.5 Bristol-Myers Squibb Recent Developments
11.3 F. Hoffmann-La Roche
11.3.1 F. Hoffmann-La Roche Company Details
11.3.2 F. Hoffmann-La Roche Business Overview
11.3.3 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Introduction
11.3.4 F. Hoffmann-La Roche Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
11.3.5 F. Hoffmann-La Roche Recent Developments
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck PD-1 and PD-L1 Immunotherapy Introduction
11.4.4 Merck Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
11.4.5 Merck Recent Developments
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer PD-1 and PD-L1 Immunotherapy Introduction
11.5.4 Pfizer Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
11.5.5 Pfizer Recent Developments
11.6 Roche
11.6.1 Roche Company Details
11.6.2 Roche Business Overview
11.6.3 Roche PD-1 and PD-L1 Immunotherapy Introduction
11.6.4 Roche Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
11.6.5 Roche Recent Developments
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis PD-1 and PD-L1 Immunotherapy Introduction
11.7.4 Novartis Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
11.7.5 Novartis Recent Developments
11.8 Jiangsu HengRui Medicine
11.8.1 Jiangsu HengRui Medicine Company Details
11.8.2 Jiangsu HengRui Medicine Business Overview
11.8.3 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Introduction
11.8.4 Jiangsu HengRui Medicine Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
11.8.5 Jiangsu HengRui Medicine Recent Developments
11.9 Innovent
11.9.1 Innovent Company Details
11.9.2 Innovent Business Overview
11.9.3 Innovent PD-1 and PD-L1 Immunotherapy Introduction
11.9.4 Innovent Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
11.9.5 Innovent Recent Developments
11.10 Eli Lilly
11.10.1 Eli Lilly Company Details
11.10.2 Eli Lilly Business Overview
11.10.3 Eli Lilly PD-1 and PD-L1 Immunotherapy Introduction
11.10.4 Eli Lilly Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
11.10.5 Eli Lilly Recent Developments
11.11 GlaxoSmithKline
11.11.1 GlaxoSmithKline Company Details
11.11.2 GlaxoSmithKline Business Overview
11.11.3 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Introduction
11.11.4 GlaxoSmithKline Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
11.11.5 GlaxoSmithKline Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
FEATURED COMPANIES
Astrazeneca plc
GlaxoSmithKline PLC
Novartis
Pfizer Inc
Bristol–Myers Squibb
F.Hoffmann-La Roche
Merck
Roche
Jiangsu Hengrui Medicine
Innovent
Eli Lilly
List of Tables
    Table 1. Global PD-1 and PD-L1 Immunotherapy Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of PD-1 inhibitor
    Table 3. Key Players of PD-L1 inhibitor
    Table 4. Global PD-1 and PD-L1 Immunotherapy Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 5. Global PD-1 and PD-L1 Immunotherapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 6. Global PD-1 and PD-L1 Immunotherapy Market Size by Region (2019-2024) & (US$ Million)
    Table 7. Global PD-1 and PD-L1 Immunotherapy Market Share by Region (2019-2024)
    Table 8. Global PD-1 and PD-L1 Immunotherapy Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 9. Global PD-1 and PD-L1 Immunotherapy Market Share by Region (2025-2030)
    Table 10. PD-1 and PD-L1 Immunotherapy Market Trends
    Table 11. PD-1 and PD-L1 Immunotherapy Market Drivers
    Table 12. PD-1 and PD-L1 Immunotherapy Market Challenges
    Table 13. PD-1 and PD-L1 Immunotherapy Market Restraints
    Table 14. Global PD-1 and PD-L1 Immunotherapy Revenue by Players (2019-2024) & (US$ Million)
    Table 15. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Players (2019-2024)
    Table 16. Global Top PD-1 and PD-L1 Immunotherapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-1 and PD-L1 Immunotherapy as of 2023)
    Table 17. Global PD-1 and PD-L1 Immunotherapy Industry Ranking 2022 VS 2023 VS 2024
    Table 18. Global 5 Largest Players Market Share by PD-1 and PD-L1 Immunotherapy Revenue (CR5 and HHI) & (2019-2024)
    Table 19. Global Key Players of PD-1 and PD-L1 Immunotherapy, Headquarters and Area Served
    Table 20. Global Key Players of PD-1 and PD-L1 Immunotherapy, Product and Application
    Table 21. Global Key Players of PD-1 and PD-L1 Immunotherapy, Product and Application
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global PD-1 and PD-L1 Immunotherapy Market Size by Type (2019-2024) & (US$ Million)
    Table 24. Global PD-1 and PD-L1 Immunotherapy Revenue Market Share by Type (2019-2024)
    Table 25. Global PD-1 and PD-L1 Immunotherapy Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 26. Global PD-1 and PD-L1 Immunotherapy Revenue Market Share by Type (2025-2030)
    Table 27. Global PD-1 and PD-L1 Immunotherapy Market Size by Application (2019-2024) & (US$ Million)
    Table 28. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Application (2019-2024)
    Table 29. Global PD-1 and PD-L1 Immunotherapy Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 30. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Application (2025-2030)
    Table 31. North America PD-1 and PD-L1 Immunotherapy Market Size by Type (2019-2024) & (US$ Million)
    Table 32. North America PD-1 and PD-L1 Immunotherapy Market Size by Type (2025-2030) & (US$ Million)
    Table 33. North America PD-1 and PD-L1 Immunotherapy Market Size by Application (2019-2024) & (US$ Million)
    Table 34. North America PD-1 and PD-L1 Immunotherapy Market Size by Application (2025-2030) & (US$ Million)
    Table 35. North America PD-1 and PD-L1 Immunotherapy Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 36. North America PD-1 and PD-L1 Immunotherapy Market Size by Country (2019-2024) & (US$ Million)
    Table 37. North America PD-1 and PD-L1 Immunotherapy Market Size by Country (2025-2030) & (US$ Million)
    Table 38. Europe PD-1 and PD-L1 Immunotherapy Market Size by Type (2019-2024) & (US$ Million)
    Table 39. Europe PD-1 and PD-L1 Immunotherapy Market Size by Type (2025-2030) & (US$ Million)
    Table 40. Europe PD-1 and PD-L1 Immunotherapy Market Size by Application (2019-2024) & (US$ Million)
    Table 41. Europe PD-1 and PD-L1 Immunotherapy Market Size by Application (2025-2030) & (US$ Million)
    Table 42. Europe PD-1 and PD-L1 Immunotherapy Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 43. Europe PD-1 and PD-L1 Immunotherapy Market Size by Country (2019-2024) & (US$ Million)
    Table 44. Europe PD-1 and PD-L1 Immunotherapy Market Size by Country (2025-2030) & (US$ Million)
    Table 45. China PD-1 and PD-L1 Immunotherapy Market Size by Type (2019-2024) & (US$ Million)
    Table 46. China PD-1 and PD-L1 Immunotherapy Market Size by Type (2025-2030) & (US$ Million)
    Table 47. China PD-1 and PD-L1 Immunotherapy Market Size by Application (2019-2024) & (US$ Million)
    Table 48. China PD-1 and PD-L1 Immunotherapy Market Size by Application (2025-2030) & (US$ Million)
    Table 49. Asia PD-1 and PD-L1 Immunotherapy Market Size by Type (2019-2024) & (US$ Million)
    Table 50. Asia PD-1 and PD-L1 Immunotherapy Market Size by Type (2025-2030) & (US$ Million)
    Table 51. Asia PD-1 and PD-L1 Immunotherapy Market Size by Application (2019-2024) & (US$ Million)
    Table 52. Asia PD-1 and PD-L1 Immunotherapy Market Size by Application (2025-2030) & (US$ Million)
    Table 53. Asia PD-1 and PD-L1 Immunotherapy Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 54. Asia PD-1 and PD-L1 Immunotherapy Market Size by Region (2019-2024) & (US$ Million)
    Table 55. Asia PD-1 and PD-L1 Immunotherapy Market Size by Region (2025-2030) & (US$ Million)
    Table 56. Middle East, Africa, and Latin America PD-1 and PD-L1 Immunotherapy Market Size by Type (2019-2024) & (US$ Million)
    Table 57. Middle East, Africa, and Latin America PD-1 and PD-L1 Immunotherapy Market Size by Type (2025-2030) & (US$ Million)
    Table 58. Middle East, Africa, and Latin America PD-1 and PD-L1 Immunotherapy Market Size by Application (2019-2024) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America PD-1 and PD-L1 Immunotherapy Market Size by Application (2025-2030) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America PD-1 and PD-L1 Immunotherapy Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 61. Middle East, Africa, and Latin America PD-1 and PD-L1 Immunotherapy Market Size by Country (2019-2024) & (US$ Million)
    Table 62. Middle East, Africa, and Latin America PD-1 and PD-L1 Immunotherapy Market Size by Country (2025-2030) & (US$ Million)
    Table 63. AstraZeneca Company Details
    Table 64. AstraZeneca Business Overview
    Table 65. AstraZeneca PD-1 and PD-L1 Immunotherapy Product
    Table 66. AstraZeneca Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024) & (US$ Million)
    Table 67. AstraZeneca Recent Developments
    Table 68. Bristol-Myers Squibb Company Details
    Table 69. Bristol-Myers Squibb Business Overview
    Table 70. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Product
    Table 71. Bristol-Myers Squibb Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024) & (US$ Million)
    Table 72. Bristol-Myers Squibb Recent Developments
    Table 73. F. Hoffmann-La Roche Company Details
    Table 74. F. Hoffmann-La Roche Business Overview
    Table 75. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Product
    Table 76. F. Hoffmann-La Roche Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024) & (US$ Million)
    Table 77. F. Hoffmann-La Roche Recent Developments
    Table 78. Merck Company Details
    Table 79. Merck Business Overview
    Table 80. Merck PD-1 and PD-L1 Immunotherapy Product
    Table 81. Merck Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024) & (US$ Million)
    Table 82. Merck Recent Developments
    Table 83. Pfizer Company Details
    Table 84. Pfizer Business Overview
    Table 85. Pfizer PD-1 and PD-L1 Immunotherapy Product
    Table 86. Pfizer Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024) & (US$ Million)
    Table 87. Pfizer Recent Developments
    Table 88. Roche Company Details
    Table 89. Roche Business Overview
    Table 90. Roche PD-1 and PD-L1 Immunotherapy Product
    Table 91. Roche Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024) & (US$ Million)
    Table 92. Roche Recent Developments
    Table 93. Novartis Company Details
    Table 94. Novartis Business Overview
    Table 95. Novartis PD-1 and PD-L1 Immunotherapy Product
    Table 96. Novartis Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024) & (US$ Million)
    Table 97. Novartis Recent Developments
    Table 98. Jiangsu HengRui Medicine Company Details
    Table 99. Jiangsu HengRui Medicine Business Overview
    Table 100. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Product
    Table 101. Jiangsu HengRui Medicine Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024) & (US$ Million)
    Table 102. Jiangsu HengRui Medicine Recent Developments
    Table 103. Innovent Company Details
    Table 104. Innovent Business Overview
    Table 105. Innovent PD-1 and PD-L1 Immunotherapy Product
    Table 106. Innovent Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024) & (US$ Million)
    Table 107. Innovent Recent Developments
    Table 108. Eli Lilly Company Details
    Table 109. Eli Lilly Business Overview
    Table 110. Eli Lilly PD-1 and PD-L1 Immunotherapy Product
    Table 111. Eli Lilly Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024) & (US$ Million)
    Table 112. Eli Lilly Recent Developments
    Table 113. GlaxoSmithKline Company Details
    Table 114. GlaxoSmithKline Business Overview
    Table 115. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Product
    Table 116. GlaxoSmithKline Revenue in PD-1 and PD-L1 Immunotherapy Business (2019-2024) & (US$ Million)
    Table 117. GlaxoSmithKline Recent Developments
    Table 118. Research Programs/Design for This Report
    Table 119. Key Data Information from Secondary Sources
    Table 120. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global PD-1 and PD-L1 Immunotherapy Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global PD-1 and PD-L1 Immunotherapy Market Share by Type: 2023 VS 2030
    Figure 3. PD-1 inhibitor Features
    Figure 4. PD-L1 inhibitor Features
    Figure 5. Global PD-1 and PD-L1 Immunotherapy Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 6. Global PD-1 and PD-L1 Immunotherapy Market Share by Application: 2023 VS 2030
    Figure 7. Solid Tumors Case Studies
    Figure 8. Blood-related Tumors Case Studies
    Figure 9. PD-1 and PD-L1 Immunotherapy Report Years Considered
    Figure 10. Global PD-1 and PD-L1 Immunotherapy Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 11. Global PD-1 and PD-L1 Immunotherapy Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 12. Global PD-1 and PD-L1 Immunotherapy Market Share by Region: 2023 VS 2030
    Figure 13. Global PD-1 and PD-L1 Immunotherapy Market Share by Players in 2023
    Figure 14. Global Top PD-1 and PD-L1 Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-1 and PD-L1 Immunotherapy as of 2023)
    Figure 15. The Top 10 and 5 Players Market Share by PD-1 and PD-L1 Immunotherapy Revenue in 2023
    Figure 16. North America PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 17. North America PD-1 and PD-L1 Immunotherapy Market Share by Type (2019-2030)
    Figure 18. North America PD-1 and PD-L1 Immunotherapy Market Share by Application (2019-2030)
    Figure 19. North America PD-1 and PD-L1 Immunotherapy Market Share by Country (2019-2030)
    Figure 20. United States PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 21. Canada PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 22. Europe PD-1 and PD-L1 Immunotherapy Market Size YoY (2019-2030) & (US$ Million)
    Figure 23. Europe PD-1 and PD-L1 Immunotherapy Market Share by Type (2019-2030)
    Figure 24. Europe PD-1 and PD-L1 Immunotherapy Market Share by Application (2019-2030)
    Figure 25. Europe PD-1 and PD-L1 Immunotherapy Market Share by Country (2019-2030)
    Figure 26. Germany PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 27. France PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 28. U.K. PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. Italy PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. Russia PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. Nordic Countries PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. China PD-1 and PD-L1 Immunotherapy Market Size YoY (2019-2030) & (US$ Million)
    Figure 33. China PD-1 and PD-L1 Immunotherapy Market Share by Type (2019-2030)
    Figure 34. China PD-1 and PD-L1 Immunotherapy Market Share by Application (2019-2030)
    Figure 35. Asia PD-1 and PD-L1 Immunotherapy Market Size YoY (2019-2030) & (US$ Million)
    Figure 36. Asia PD-1 and PD-L1 Immunotherapy Market Share by Type (2019-2030)
    Figure 37. Asia PD-1 and PD-L1 Immunotherapy Market Share by Application (2019-2030)
    Figure 38. Asia PD-1 and PD-L1 Immunotherapy Market Share by Region (2019-2030)
    Figure 39. Japan PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 40. South Korea PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 41. China Taiwan PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 42. Southeast Asia PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. India PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. Australia PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. Middle East, Africa, and Latin America PD-1 and PD-L1 Immunotherapy Market Size YoY (2019-2030) & (US$ Million)
    Figure 46. Middle East, Africa, and Latin America PD-1 and PD-L1 Immunotherapy Market Share by Type (2019-2030)
    Figure 47. Middle East, Africa, and Latin America PD-1 and PD-L1 Immunotherapy Market Share by Application (2019-2030)
    Figure 48. Middle East, Africa, and Latin America PD-1 and PD-L1 Immunotherapy Market Share by Country (2019-2030)
    Figure 49. Brazil PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 50. Mexico PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 51. Turkey PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 52. Saudi Arabia PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 53. Israel PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 54. GCC Countries PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. AstraZeneca Revenue Growth Rate in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
    Figure 56. Bristol-Myers Squibb Revenue Growth Rate in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
    Figure 57. F. Hoffmann-La Roche Revenue Growth Rate in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
    Figure 58. Merck Revenue Growth Rate in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
    Figure 59. Pfizer Revenue Growth Rate in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
    Figure 60. Roche Revenue Growth Rate in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
    Figure 61. Novartis Revenue Growth Rate in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
    Figure 62. Jiangsu HengRui Medicine Revenue Growth Rate in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
    Figure 63. Innovent Revenue Growth Rate in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
    Figure 64. Eli Lilly Revenue Growth Rate in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
    Figure 65. GlaxoSmithKline Revenue Growth Rate in PD-1 and PD-L1 Immunotherapy Business (2019-2024)
    Figure 66. Bottom-up and Top-down Approaches for This Report
    Figure 67. Data Triangulation
    Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

Global PD 1 and PD L1 Antibody Market Insights Forecast to 2030
Global Anti PD 1 MAb Market Insights Forecast to 2030
Global Cancer Immunotherapy Drug Discovery Outsourcing Market Insights Forecast to 2030
Global Systemic Lupus Erythematosus Treatment Market Insights Forecast to 2030
Global Drug Delivery in Cancer Market Insights Forecast to 2030
Global Photodynamic Therapy Market Insights Forecast to 2030
PD L1 Inhibitors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Burn Therapy Market Insights Forecast to 2030
Global Cryotherapy Market Insights Forecast to 2030
Global Angioedema Treatment Market Insights Forecast to 2030
Global Metabolic Disorder Therapeutics Market Insights Forecast to 2030
Global Metastatic Colorectal Cancer Drug Market Insights Forecast to 2030
Global TCR T Therapy Reagent Market Insights Forecast to 2030
Global CTLA 4 Protein Market Insights Forecast to 2030
Global Osteoporosis Treatment Market Insights Forecast to 2030
Global Systemic Inflammatory Response Syndrome Treatment Market Insights Forecast to 2030
Global Burn Injury Treatment Market Insights Forecast to 2030
Global Rheumatic Disorders Drug Market Insights Forecast to 2030
Global Nasal Polyps Treatment Market Insights Forecast to 2030
Global Patient Intake Software Market Insights Forecast to 2030

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-5L19798
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-28I6901
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22R9736
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-29A2598
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions